Eli Lilly's Mounjaro Misses Out on Dedicated Sleep Apnea Approval in Europe

In a significant development for the pharmaceutical industry, Eli Lilly's diabetes drug, Mounjaro, has been denied a separate label for the treatment of sleep apnea in Europe. This decision, announced recently, highlights the ongoing complexities within the regulatory landscape governing medical treatments and their approvals across different markets.

Continue reading